ArticleRadiation oncology (London, England)2021

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).

Catherine R Hanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.